Search

Displaying results 1331 - 1340 of 3889 in total
  1. Drug

    Ethynodiol diacetate

    go.drugbank.com/drugs/DB00823
    Approved

    are sometimes used as a synonym for ethynodiol diacetate, what is usually being referred to is actually ethynodiol diacetate and not ethynodiol (which is a separate drug that has never been marketed, see

    Categories: Genito Urinary System and Sex Hormones, Sex Hormones and Modulators of the Genital System
  2. Drug

    Rifapentine

    go.drugbank.com/drugs/DB01201
    ApprovedInvestigational

    Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.

  3. Drug

    Daleuton

    go.drugbank.com/drugs/DB00154
    InvestigationalNutraceutical

    A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.

  4. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    [A257325,A257335,L45310] Compared to [irbesartan], sparsentan reduces proteinuria to a greater extent.

  5. Indication

    Mesothelioma

    go.drugbank.com/conditions/DBCOND0017375
    Drugs: Gemcitabine · Mitomycin
    Synonyms: Mesothelioma (Part G)
  6. Drug

    Metoclopramide

    go.drugbank.com/drugs/DB01233
    ApprovedInvestigational

    [L8417] One unique property of this drug is that it does not increase gastric acid secretion.

    Categories: para-Aminobenzoates
  7. Drug

    Sarilumab

    go.drugbank.com/drugs/DB11767
    ApprovedInvestigational

    [A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid

  8. Drug

    Flupentixol

    go.drugbank.com/drugs/DB00875
    ApprovedInvestigationalWithdrawn

    It is used for the management of chronic schizophrenia in patients whose main manifestations do not include excitement, agitation or hyperactivity.

  9. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3). It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and ha...

  10. Drug

    Vemurafenib

    go.drugbank.com/drugs/DB08881
    ApprovedInvestigational

    Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxiko...

    Categories: Genito Urinary System and Sex Hormones